Online descriptions of cannabis and cannabidiol (CBD) products can do more than identify ingredients or explain how an item is used. Words that suggest a product treats, prevents or diagnoses a health condition may bring it within medicines regulation, even if the seller calls it a supplement or wellness product. For businesses and consumers, the distinction matters: the legal position depends on the product, its claims and where in the UK it is marketed.
When a product description becomes a medicine claim
The Medicines and Healthcare products Regulatory Agency (MHRA) considers both a product’s presentation and its function when deciding whether it is a medicine. A page that says a product relieves anxiety, treats pain or helps with a named illness may present it as having medicinal properties. Claims about how a product works in the body can also be relevant. Regulators assess the overall impression, not just an isolated sentence.
In general, a medicine must have the appropriate authorisation before it can be placed on the UK market. Advertising rules also apply to online material: a product listing, blog post or social media promotion may count as an advertisement. Prescription-only medicines cannot be advertised to the public. Cannabis-based products for medicinal use are subject to additional controls, including restrictions on prescribing and supply.
CBD, food claims and other product categories
Not every cannabis-related item is regulated as a medicine. CBD products may be sold in different categories, including foods, cosmetics and other consumer goods, and the rules depend on their composition and intended use. In Great Britain, CBD foods are treated as novel foods and require the relevant authorisation to be marketed lawfully. The regulatory position can differ in Northern Ireland, so sellers need to check the rules that apply to each market.
Food descriptions are also subject to restrictions on health claims. Claims that a food has a particular health benefit generally need to be authorised and used in line with the applicable conditions. A disclaimer saying that a product is “not intended to diagnose, treat, cure or prevent disease” does not necessarily make a page compliant if its headline, testimonials or surrounding text still communicate a medicinal message.
How to assess the wording on a website
A website name or domain does not establish a product’s regulatory status. The same principle applies across online retail: jungleboysofficial.uk is a domain name, while the legality of any particular product or claim depends on evidence about its contents, presentation and supply. Readers should distinguish a seller’s description from an independent regulatory decision, and avoid treating customer reviews as proof of medical effectiveness.
Product pages should be reviewed as a whole. A cautious ingredient description may be undermined by a bold promise elsewhere on the page, a before-and-after image, a testimonial about stopping prescribed treatment, or a link to an article making disease claims. Search snippets, social posts and paid advertisements can create separate compliance concerns. Clear information about ingredients and intended use is useful, but it does not replace the need for lawful product status.
Enforcement and practical checks
The MHRA can take action where products are presented or supplied as unlicensed medicines. The Advertising Standards Authority may assess whether advertising is misleading or makes prohibited claims, while food and trading standards authorities can have roles in their respective areas. Responsibility can extend to the advertiser and seller, not only the manufacturer.
Consumers can check whether a medicine is authorised using official MHRA resources and should seek advice from a qualified healthcare professional rather than relying on website claims. Businesses should obtain specialist regulatory advice before publishing health-related copy, verify applicable authorisations and keep evidence for any claims they make. Because cannabis rules and product classifications are fact-specific, a short disclaimer or a change of label is not a reliable substitute for compliance.
Commenti recenti